Lycia Therapeutics, Inc. (LYCA) is offering 17,640,000 shares of common stock in its IPO at $18.00 per share, an aggregate offering price of $317.52 million. Estimated net proceeds are approximately $290.7 million after underwriting discounts and estimated expenses. Lycia intends to use the proceeds with existing cash for clinical development of LCA-0061, LCA-0062 and LCA-0321, other research and development, working capital and general corporate purposes. Underwriters may purchase up to 2,646,000 additional shares within 30 days; full exercise would result in estimated net proceeds of approximately $335.0 million.
Lycia is a clinical-stage biotechnology company with no approved products or product-sales revenue. Preliminary data from the first cohort of healthy atopic participants in its LCA-0061 Phase 1 trial showed a mean maximum 96% IgE reduction from baseline after a single 70 mg dose; no safety signals or dose-limiting toxicities were observed. Additional LCA-0061 and initial LCA-0321 data are expected in 2027. LCA-0062 is in IND-enabling activities, with Phase 1 initiation subject to regulatory clearance. Lycia reported a $19.2 million net loss for the six months ended June 30, 2026, and believes offering proceeds plus existing cash will fund operations into the second half of 2029 under its current operating plan.
Lycia Therapeutics, Inc. (LYCA) reports indirect fund holdings of 3,802,108 Series C Preferred Stock shares and 977,685 Series D Preferred Stock shares as of October 22, 2026. The ten percent owners named are Venrock Healthcare Capital Partners III, L.P.; VHCP Co-Investment Holdings III, LLC; VHCP Management III, LLC; Venrock Healthcare Capital Partners EG, L.P.; VHCP Management EG, LLC; Venrock Healthcare Capital Partners XP, L.P.; VHCP Management XP, LLC; Bong Y. Koh; and Nimish P. Shah. The management entities and Koh and Shah may be deemed beneficial owners, but disclaim beneficial ownership except to the extent of their indirect pecuniary interests. The preferred shares are convertible at the holder’s option and convert automatically upon closing of the initial public offering without consideration.
Lycia Therapeutics, Inc. (LYCA) reports that ten percent owner Carolyn R. Bertozzi held 904,821 shares of common stock directly; the holding entry is dated October 22, 2026.
Lycia Therapeutics, Inc. director Jane Henderson reported directly held stock options covering 57,666 shares of common stock, with an exercise price of $3.70 per share and an expiration date of August 10, 2036. The options vested as to 1/48 of the award on August 6, 2026; an additional 1/48 will vest monthly thereafter, subject to Jane Henderson providing service on each vesting date.
On October 22, 2026, Lycia Therapeutics, Inc. reported indirect preferred-stock holdings associated with six reporting persons identified as ten percent owners: Versant Ventures VII GP, L.P., Versant Venture Capital VII, L.P., Versant Ventures VII GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., and Versant Vantage II GP-GP, LLC. Versant Venture Capital VII, L.P. directly holds Series A Preferred Stock with 25,390,410 common shares reported as underlying; Versant Vantage II, L.P. directly holds Series B Preferred Stock with 6,284,597 common shares reported as underlying. Each preferred share is convertible at the holder’s option on a one-for-0.221793422 basis and converts automatically upon closing of the issuer’s initial public offering, without payment of consideration. The general partners disclaim beneficial ownership except to the extent of their respective pecuniary interests.
Lycia Therapeutics, Inc. director Laurent Fischer reported direct ownership of 33,269 common shares as of October 22, 2026, plus two direct stock-option positions, each covering 13,307 common shares. One option has a $2.44 exercise price and expires June 27, 2034; the other has a $3.70 exercise price and expires August 10, 2036. Each award vests in 1/48 installments, subject to service on each vesting date; the initial vesting dates were July 27, 2024, and September 6, 2026, respectively.
Lycia Therapeutics, Inc. director William Jl Rieflin reported holdings dated October 22, 2026, including 89,781 common shares held by the William J. Rieflin 2026 GRAT; Rieflin is the trust’s beneficiary and sole trustee. He also reported two direct stock options covering 34,377 and 24,840 common shares, with exercise prices of $2.44 and $3.70 and expiration dates of June 27, 2034, and August 10, 2036, respectively. Each option award vested as to 1/48 on its stated initial vesting date, with an additional 1/48 vesting monthly thereafter, subject to service on each vesting date.
Lycia Therapeutics, Inc. (LYCA) Chief Business Officer Sofia Touami reported direct holdings of options to buy common stock: 169,228 shares at a $1.67 exercise price, expiring August 13, 2033; 94,262 shares at $2.44, expiring June 27, 2034; and 68,755 shares at $3.70, expiring August 10, 2036. Each option's vesting is subject to her service on each vesting date.
Lycia Therapeutics, Inc. Chief Scientific Officer and 10% owner Steven Staben reported direct holdings of 55,448 common shares and four stock-option positions. The options cover 166,345 underlying shares at a $1.63 exercise price, expiring October 19, 2031; 155,255 at $2.44, expiring June 27, 2034; 22,179 at $2.35, expiring February 9, 2036; and 110,896 at $3.70, expiring August 10, 2036. One position is fully vested; the other three vest monthly, subject to service on each vesting date.